ArticleFrontiers in immunology2026
Multidisciplinary treatment incorporating autologous DC-CIK cell therapy induces long-term survival in advanced pancreatic cancer: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is widely acknowledged as one of the most aggressive malignancies of the digestive system. More than 80% of patients are diagnosed at an advanced stage with an extremely poor prognosis. While contemporary combination chemotherapy and the novel RAS inhibitor daraxonrasib have modestly prolonged survival, clinical benefits remain limited, necessitating less toxic yet more substantial and durable therapeutic strategies. Herein, we report a case of a patient with advanced metastatic adenocarcinoma who achieved disease stability and long-term survival following multidisciplinary treatment incorporating autologous DC-CIK cell therapy. The patient was a 73-year-old male diagnosed with poorly differentiated pancreatic ductal carcinoma 9 years ago. After surgery, he developed pelvic implantation metastases and subsequently received multi-line chemotherapy and radiotherapy. Thereafter, he completed five cycles of DC-CIK cell infusion at a dose of 5×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.